Drug Trial Radar · NCT01838681
Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Last checked: Nov 19, 2026Latest source record: Aug 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,986
Actual
Start
Jun 2013
Primary completion
Jun 2016
Study completion Jun 2016
Sponsor
- Lead sponsor
- H. Lundbeck A/SIndustry
- Sponsor type
- Industry
- Collaborators
- Otsuka Pharmaceutical Co., Ltd.
- First posted
- Apr 24, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).
Conditions
- Major Depressive Disorder
Interventions
PlaceboDrug
Once daily, tablets, orally
BrexpiprazoleDrug
1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day
ADTDrug
Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Full Remission During the Randomised Treatment PeriodTime frame: From randomisation to end of Period B (24 weeks)
Locations
107 sites in 16 countries. Site status is shown where the registry gives one.
US041
Little Rock, Arkansas
US043
Cerritos, California
US042
Temecula, California
US053
Flowood, Mississippi
US040
Brooklyn, New York
US046
Houston, Texas
US052
Houston, Texas
US047
Milwaukee, Wisconsin
BG007
Kardzhali, Bulgaria
BG002
Pazardzhik, Bulgaria
BG003
Rousse, Bulgaria
BG001
Sofia, Bulgaria
BG004
Sofia, Bulgaria
BG005
Varna, Bulgaria
BG006
Varna, Bulgaria
CA003
Burlington, Canada
CA004
Edmonton, Alberta, Canada
CA001
Kingston, Canada
CA002
Montral, Canada
CA005
Montreal, Canada
EE002
Tallinn, Estonia
EE003
Tallinn, Estonia
EE006
Tallinn, Estonia
EE001
Tartu, Estonia
EE005
Tartu, Estonia
EE004
Võru, Estonia
FI002
Helsinki, Finland
FI003
Helsinki, Finland
FI006
Helsinki, Finland
FI001
Kuopio, Finland
FI007
Pori, Finland
FI009
Tampere, Finland
DE007
Berlin, Germany
DE014
Berlin, Germany
DE015
Berlin, Germany
DE006
Bielefeld, Germany
DE010
Bochum, Germany
DE012
Gelsenkirchen, Germany
DE009
Hanover, Germany
DE022
Hattingen, Germany
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.